• Something wrong with this record ?

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

L. Peyrin-Biroulet, JR. Allegretti, DT. Rubin, B. Bressler, M. Germinaro, KG. Huang, N. Shipitofsky, H. Zhang, R. Wilson, C. Han, BG. Feagan, WJ. Sandborn, J. Panés, T. Hisamatsu, GR. Lichtenstein, BE. Sands, A. Dignass, QUASAR Study Group

. 2023 ; 165 (6) : 1443-1457. [pub] 20230901

Language English Country United States

Document type Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc24000505

BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy. METHODS: In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease ≥30% and ≥2 points, rectal bleeding subscore ≥1-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period). RESULTS: The primary analysis population included patients with baseline modified Mayo scores ≥5 and ≤9 (intravenous guselkumab 200 mg, n = 101; 400 mg, n = 107; placebo, n = 105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) vs placebo (27.6%; both P < .001). Greater proportions of guselkumab-treated vs placebo-treated patients achieved all major secondary endpoints (clinical remission, symptomatic remission, endoscopic improvement, histo-endoscopic mucosal improvement, and endoscopic normalization) at week 12. Among guselkumab week-12 clinical nonresponders, 54.3% and 50.0% of patients in the 200- and 400-mg groups, respectively, achieved clinical response at week 24. Safety was similar among guselkumab and placebo groups. CONCLUSIONS: Guselkumab intravenous induction was effective vs placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups. CLINICALTRIALS: gov number: NCT04033445.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000505
003      
CZ-PrNML
005      
20240213093224.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.gastro.2023.08.038 $2 doi
035    __
$a (PubMed)37659673
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peyrin-Biroulet, Laurent $u Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France; INSERM, NGERE, University of Lorraine, F-54000 Nancy, France; INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France; FHU-CURE, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France; Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Center, 92200 Neuilly sur Seine, France; Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
245    10
$a Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study / $c L. Peyrin-Biroulet, JR. Allegretti, DT. Rubin, B. Bressler, M. Germinaro, KG. Huang, N. Shipitofsky, H. Zhang, R. Wilson, C. Han, BG. Feagan, WJ. Sandborn, J. Panés, T. Hisamatsu, GR. Lichtenstein, BE. Sands, A. Dignass, QUASAR Study Group
520    9_
$a BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy. METHODS: In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease ≥30% and ≥2 points, rectal bleeding subscore ≥1-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period). RESULTS: The primary analysis population included patients with baseline modified Mayo scores ≥5 and ≤9 (intravenous guselkumab 200 mg, n = 101; 400 mg, n = 107; placebo, n = 105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) vs placebo (27.6%; both P < .001). Greater proportions of guselkumab-treated vs placebo-treated patients achieved all major secondary endpoints (clinical remission, symptomatic remission, endoscopic improvement, histo-endoscopic mucosal improvement, and endoscopic normalization) at week 12. Among guselkumab week-12 clinical nonresponders, 54.3% and 50.0% of patients in the 200- and 400-mg groups, respectively, achieved clinical response at week 24. Safety was similar among guselkumab and placebo groups. CONCLUSIONS: Guselkumab intravenous induction was effective vs placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups. CLINICALTRIALS: gov number: NCT04033445.
650    _2
$a lidé $7 D006801
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $7 D061067
650    12
$a ulcerózní kolitida $x diagnóza $x farmakoterapie $x komplikace $7 D003093
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a indukce remise $7 D012074
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Allegretti, Jessica R $u Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
700    1_
$a Rubin, David T $u University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois
700    1_
$a Bressler, Brian $u University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Germinaro, Matthew $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Huang, Kuan-Hsiang Gary $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Shipitofsky, Nicole $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Zhang, Hongyan $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Wilson, Rebbecca $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Han, Chenglong $u Janssen Research & Development, LLC, Spring House, Pennsylvania
700    1_
$a Feagan, Brian G $u Western University, London, Ontario, Canada
700    1_
$a Sandborn, William J $u University of California San Diego, La Jolla, California
700    1_
$a Panés, Julian $u Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
700    1_
$a Hisamatsu, Tadakazu $u Kyorin University, Tokyo, Japan
700    1_
$a Lichtenstein, Gary R $u University of Pennsylvania Health System, The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania, Gastroenterology Division, Philadelphia, Pennsylvania
700    1_
$a Sands, Bruce E $u Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
700    1_
$a Dignass, Axel $u Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany. Electronic address: Axel.Dignass@agaplesion.de
710    2_
$a QUASAR Study Group
773    0_
$w MED00001877 $t Gastroenterology $x 1528-0012 $g Roč. 165, č. 6 (2023), s. 1443-1457
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37659673 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093222 $b ABA008
999    __
$a ok $b bmc $g 2049266 $s 1210199
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 165 $c 6 $d 1443-1457 $e 20230901 $i 1528-0012 $m Gastroenterology $n Gastroenterology $x MED00001877
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options